Title : Current and emerging first-line systemic therapies in metastatic clear-cell renal cell carcinoma.

Pub. Date : 2019 Jul-Aug

PMID : 31646776






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Based on evidence from randomized phase III clinical trials, sunitinib and pazopanib (Tyrosine kinase inhibitors of vascular endothelial growth factor; VEGF-TKIs) are the most effective first-line options, especially in favorable and indermediate risk patients. Tyrosine vascular endothelial growth factor A Homo sapiens
2 Based on evidence from randomized phase III clinical trials, sunitinib and pazopanib (Tyrosine kinase inhibitors of vascular endothelial growth factor; VEGF-TKIs) are the most effective first-line options, especially in favorable and indermediate risk patients. Tyrosine vascular endothelial growth factor A Homo sapiens